XTLB

XTL Biopharmaceuticals
XTLB

Overview Fund Activity

6 hedge funds and large institutions have $804K invested in XTL Biopharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NI
1
Noked Israel
Israel
$344K
2
NC
2
Noked Capital
Israel
$344K
3
Morgan Stanley
3
Morgan Stanley
New York
$57K
4
Deutsche Bank
4
Deutsche Bank
Germany
$2K
5
UBS Group
5
UBS Group
Switzerland
$12K

Top Sellers

1
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$0
Name Market Value Shares Shares
Change 		Shares
Change %
NI
1
Noked Israel
Israel
$344K 198,889 +198,889 New
NC
2
Noked Capital
Israel
$344K 198,889 +198,889 New
Morgan Stanley
3
Morgan Stanley
New York
$57K 33,132 +9,600 +41%
Invesco
4
Invesco
Georgia
$45K 25,961 – –
UBS Group
5
UBS Group
Switzerland
$12K 6,671 +216 +3%
Deutsche Bank
6
Deutsche Bank
Germany
$2K 1,300 +1,300 New
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
– – -41,791 Closed
CFGS
8
Concourse Financial Group Securities
Alabama
– – – –